Diary - News All news Adocia and Lilly announce positive topline results

Adocia and Lilly announce positive topline results

Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes

Adocia (Euronext Paris: ADOC) and Eli Lilly and Company (NYSE: LLY) announced today positive topline results from a Phase 1b clinical trial under the Adocia-Lilly partnership evaluating BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Lilly. This formulation uses Adocia’s proprietary technology BioChaperone, designed to accelerate insulin absorption.

Read the press release